Skip to content

Free cash flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$757M-55.3%
NeoGenomics logo
NeoGenomicsNEO
-$13.14M+56.0%
Natera, Inc. logo
Natera, Inc.NTRA
$18.03M-20.3%
Labcorp Holdings logo
Labcorp HoldingsLH
Quest Diagnostics logo
Quest DiagnosticsDGX
Tempus AI, Inc. logo
Tempus AI, Inc.TEM

Other financials

Income statement

See full
Revenue$71.1M-3.2%
Gross profit$21.5M-24.2%
Operating income-$34.6M-74.9%
Net income-$24.8M-115%
EPS (diluted)-$0.80-116%

Balance sheet

See full
Cash & equivalents$23.4M-65.2%
Total debt$8.2M+40.5%
Total equity$1.0B-6.9%
Total assets$1.2B-4.1%

Cash flow

See full
Operating cash flow$7.1M+260%
CapEx$5.2M+10.3%

Valuation

See full
Market cap$552.11M-7.1%
Enterprise value$536.92M+0.7%
P/S1.7×-0.3×

Profitability

See full
Gross margin38.7%-0.1pp
Operating margin-33.1%+17.4pp
Net margin-23%+43.3pp
FCF margin-36.9%

Returns & leverage

See full
Return on equity-6.8%+48.2pp
Debt / equity0.0×
Current ratio5.3×-1.0×

Where this comes from

Calculated from Fulgent Genetics, Inc.’s reported figures.

The official record: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Fulgent Genetics, Inc.'s free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Fulgent Genetics, Inc.'s free cash flow?
Fulgent Genetics, Inc. (FLGT) reported free cash flow of $1.9M in Q1 2026.
How has Fulgent Genetics, Inc.'s free cash flow changed year-over-year?
Fulgent Genetics, Inc.'s free cash flow increased by 120.7% year-over-year, from -$9.15M to $1.9M.
What is the long-term trend for Fulgent Genetics, Inc.'s free cash flow?
Over 3 years (2021 to 2025), Fulgent Genetics, Inc.'s free cash flow has grown at a -36.9% compound annual growth rate (CAGR), from $514.77M to -$129.27M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.